Clinical Trial to Evaluate the Addition to an Antiretroviral Treatment of a Probiotic

Clinical Trial, Randomized and Controlled With Placebo to Evaluate the Addition to an Antiretroviral Treatment of a Probiotic, Only or in Conjunction of a Pre-biotical, in Adults Infected by Hiv-1 With a cd4 Record Less Than 500 Cells / mm3

The main purpose of this study is to evaluate a therapy for the inflammaging (premature aging).

It's been demonstrated that the HIV-1 virus is associated to the reduction of the microbiota. Some studies suggest that because of this bacterial reduction, the premature aging appears. So this study aims to demonstrate that our probiotic can balance the microbiota as a preventive solution for the inflammaging.

Inclusion Criteria:

• Older than 18 years old.
• Documented HIV-1 infection.
• Be in treatment with these antiretrovirals (INI, IP, ITINAN) during 12 months.
• HIV-1 Viral titer <50 copies/mL during 6 months.
• CD4> 500 cells/mm3.

Exclusion Criteria:

• Treatment with antibiotics.
• Severe diseases actives.
• Defining diseases of AIDS in the previous year.
• Gut surgery except appendectomy or cholecystectomy.
• Pregnancy.
• Any diet deviation (vegans).
• Other probiotic treatment.